お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:糖尿病性網膜症:世界の治療薬予測・市場分析 (~2029年)
市場調査レポート
商品コード
956057

糖尿病性網膜症:世界の治療薬予測・市場分析 (~2029年)

Diabetic Retinopathy - Global Drug Forecast and Market Analysis to 2029

出版日: | 発行: GlobalData | ページ情報: 英文 | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.93円
糖尿病性網膜症:世界の治療薬予測・市場分析 (~2029年)
出版日: 2020年08月31日
発行: GlobalData
ページ情報: 英文
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の主要9ヶ国市場 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本、中国、オーストラリア) における糖尿病性網膜症 (DR) 向け医薬品の売上高は、2019年に約36億米ドルと推計され、10年間の予測期間にわたって、市場規模はCAGR 9.1%で推移し、2029年に86億米ドルに達すると予測されています。この成長は、DRの主要な臨床的アンメットニーズに対処し、患者のコンプライアンスを高めることが期待される長時間作用型の抗血管新生製品、局所用および経口の候補薬の発売によって推進されます。

当レポートは、世界における糖尿病性網膜症 (DR) 治療薬市場について調査し、疫学、病因、病態生理学、症状、診断、および疾患管理を含む、DR、RVO (網膜静脈閉塞症)、およびDME (糖尿病性黄斑浮腫) の概要、DR、RVO、DME治療薬の年間の市場収益、患者あたりの治療費、および4つの患者セグメントにおける治療薬の使用パターン (重度の非増殖性糖尿病性網膜症、増殖性糖尿病性網膜症、糖尿病性網膜症および網膜静脈閉塞症、糖尿病性網膜症および糖尿病性黄斑浮腫) の予測などを提供しています。

目次

第1章 目次

第2章 糖尿病性網膜症:エグゼクティブサマリー

  • 一貫した成長により、DRの市場規模は2019年から2029年の間に2倍以上へ
  • 新しい作用機序と非侵襲的な投与経路が臨床試験によって研究
  • 早期DR向けの特定の治療法が無いことは、大きなアンメットニーズ
  • 頻繁な抗VEGF注射の負担を減らすことは、医薬品開発者にとって重要な優先事項
  • 血管新生阻害剤の売上高は2029年に60億米ドルを超える
  • 医師の見解とは?

第3章 イントロダクション

  • 触媒
  • 関連レポート
  • 今後の関連レポート

第4章 疾患の概要

  • 病因と病態生理学
  • 分類または病期分類システム

第5章 疫学

  • 病気の背景
  • 危険因子と併存症
  • 世界の動向および歴史的動向
  • 予測調査手法
  • 糖尿病性網膜症の疫学予測
  • 議論

第6章 疾病管理

  • 診断の概要
  • 治療の概要
  • DR、RVO、およびDMEのための薬物療法の介入
  • 糖尿病性網膜症の非薬物療法の選択肢
  • 米国
  • EU5ヶ国
  • アジア太平洋

第7章 競争力の評価

第8章 アンメットニーズと機会の評価

第9章 パイプラインの評価

第10章 現在および将来の企業

第11章 市場の展望

第12章 付録

図表

List of Tables

  • Table 1: Diabetic Retinopathy: Key Metrics in the 9MM
  • Table 2: Stages of DR
  • Table 3: Risk Factors and Comorbidities for Diabetic Retinopathy
  • Table 4: National and International Treatment Guidelines for DR
  • Table 5: DR Disease Management - US
  • Table 6: DR Disease Management - 5EU
  • Table 7: DR Disease Management - Asia-Pacific:
  • Table 8: Marketed Drugs for DR in the 9MM, 2020
  • Table 9: Comparison of Therapeutic Classes in the DR, RVO, and DME Pipelines, 2019-2029
  • Table 10: Phase I Pipeline Products in Development for DR, RVO, and DME
  • Table 11: Roche/Genentech/Chugai's DR Portfolio Assessment, 2020
  • Table 12: Bayer's DR Portfolio Assessment, 2020
  • Table 13: Regeneron's DR Portfolio Assessment, 2020
  • Table 14: Alimera's DR Portfolio Assessment, 2020
  • Table 15: Allergan's DR Portfolio Assessment, 2020
  • Table 16: Novartis' DR Portfolio Assessment, 2020
  • Table 17: Allegro's DR Portfolio Assessment, 2020
  • Table 18: Gene Signal International's DR Portfolio Assessment, 2020
  • Table 19: Boehringer Ingelheim's DR Portfolio Assessment, 2020
  • Table 20: Oculis' DR Portfolio Assessment, 2020
  • Table 21: Araim Pharma's DR Portfolio Assessment, 2020
  • Table 22: Opthea's DR Portfolio Assessment, 2020
  • Table 23: Pfizer's DR Portfolio Assessment, 2020
  • Table 24: Clearside BioMedical's DR Portfolio Assessment, 2020
  • Table 25: EyeGene's DR Portfolio Assessment, 2020
  • Table 26: Kubota Vision's DR Portfolio Assessment, 2020
  • Table 27: Oxurion's Vision's DR Portfolio Assessment, 2020
  • Table 28: Outlook Therapeutics' DR Portfolio Assessment, 2020
  • Table 29: Kodiak Sciences' DR Portfolio Assessment, 2020
  • Table 30: DR Market - Global Drivers and Barriers, 2019-2029
  • Table 31: Key Events Impacting Sales for DR in the US, 2019-2029
  • Table 32: DR Market - Drivers and Barriers in the US, 2019-2029
  • Table 33: Key Events Impacting Sales for DR in the 5EU, 2019-2029
  • Table 34: DR Market - Drivers and Barriers in the 5EU, 2019-2029
  • Table 35: Key Events Impacting Sales for DR in Japan, 2019-2029
  • Table 36: DR Market - Global Drivers and Barriers in Japan, 2019-2029
  • Table 37: Key Events Impacting Sales for DR in China, 2019-2029
  • Table 38: DR Market - Global Drivers and Barriers in China, 2019-2029
  • Table 39: Key Events Impacting Sales for DR in Australia, 2019-2029
  • Table 40: DR Market - Global Drivers and Barriers in Australia, 2019-2029

List of Figures

  • Figure 1: Global Sales Forecast by Country for DR in 2019 and 2029
  • Figure 2: Analysis of the Company Portfolio Gap in DR During the Forecast Period
  • Figure 3: Competitive Assessment of the Ten Top-Selling Late-Stage Pipeline Agents for the Treatment of DR, RVO, and DME During the Forecast Period
  • Figure 4: Pathogenic Processes in DR, RVO and DME
  • Figure 5: 9MM, Diagnosed Prevalence of Diabetic Retinopathy Among the Diagnosed Diabetics Population, Both Sexes, %, Ages ≥20 Years, 2019
  • Figure 6: 9MM, Diagnosed Prevalence of RVO in the General Population, Both Sexes, %, Ages ≥20 Years, 2019
  • Figure 7: 9MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Diabetic Retinopathy
  • Figure 8: 9MM, Sources Used and Not Used, Diagnosed Prevalent Cases of RVO
  • Figure 9: 9MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Diabetic Retinopathy by Severity
  • Figure 10: 9MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Diabetic Macular Edema
  • Figure 11: 9MM, Sources Used, Diagnosed Prevalent Cases of Macular Edema Following BRVO
  • Figure 12: 9MM, Sources Used, Diagnosed Prevalent Cases of Macular Edema Following CRVO
  • Figure 13: 9MM, Sources Used, Diagnosed Prevalent Cases of CSME
  • Figure 14: 9MM, Diagnosed Prevalent Cases of Diabetic Retinopathy, N, Both Sexes, Ages ≥20 Years, 2019
  • Figure 15: 9MM, Age-Specific Diagnosed Prevalent Cases of Diabetic Retinopathy, N, Both Sexes, 2019
  • Figure 16: 9MM, Diagnosed Prevalent Cases of Diabetic Retinopathy by Sex, N, Ages ≥20 Years, 2019
  • Figure 17: 9MM, Diagnosed Prevalent Cases of Diabetic Retinopathy by Severity, N, Ages ≥20 Years, 2019
  • Figure 18: 9MM, Diagnosed Prevalent Cases of RVO, Both Sexes, N, Ages ≥20 Years, 2019
  • Figure 19: 9MM, Diagnosed Prevalent Cases of RVO by Age, N, Both Sexes, 2019
  • Figure 20: 9MM, Diagnosed Prevalent Cases of RVO by Sex, N, Ages ≥20 Years, 2019
  • Figure 21: 9MM, Diagnosed Prevalent Cases of DME in the Diabetic Retinopathy Population, N, Ages ≥20 Years, Both Sexes, 2019
  • Figure 22: 9MM, Diagnosed Prevalent Cases of Macular Edema Following BRVO, Both Sexes, N, Ages ≥20 Years, 2019
  • Figure 23: 9MM, Diagnosed Prevalent Cases of Macular Edema Following CRVO, Both Sexes, N, Ages ≥20 Years, 2019
  • Figure 24: 9MM, Diagnosed Prevalent Cases of CSME in the DME Population, N, Both Sexes, Ages ≥20 Years, 2019
  • Figure 25: Unmet Needs and Opportunities in DR
  • Figure 26: ETDRS Chart Used to Measure Visual Acuity
  • Figure 27: Overview of the Development Pipeline in DR
  • Figure 28: Ongoing Phase II/III Trials for Anti-VEGF Pipeline Agents in Development for DR in the 9MM
  • Figure 29: Ongoing Trials for Pipeline Agents in Development for DR in the 9MM
  • Figure 30: Competitive Assessment of the Therapeutic Classes in the Late-Stage pipeline that GlobalData Expects to be Licensed for the Treatment of DR During the Forecast Period
  • Figure 31: Company Portfolio Gap Analysis in DR, 2019-2029
  • Figure 32: Values of Co-development Deals in the 9MM, 2010-Q2 2020
  • Figure 33: Global (9MM) Sales Forecast by Country for DR in 2019 and 2029
  • Figure 34: Sales Forecast by Therapeutic Class for DR in the 9MM, 2019 and 2029
  • Figure 35: DR Sales Forecast in the 9MM by Drug, 2019 and 2029
  • Figure 36: Sales Forecast by Drug for DR in the US in 2019 and 2029
  • Figure 37: Sales Forecast by Drug for DR in the 5EU in 2019 and 2029
  • Figure 38: Sales Forecast by Drug for DR in Japan in 2019 and 2029
  • Figure 39: Sales Forecast by Drug for DR in China in 2019 and 2029
  • Figure 40: Sales Forecast by Drug for DR in Australia in 2019 and 2029
目次
Product Code: GDHC199PIDR

Diabetic retinopathy (DR) is a sight-threatening, prevalent complication of type 1 and 2 diabetes which is characterized by damage to the small blood vessels in the retina. As the most common microvascular complication of diabetes, more than 60% of patients will experience DR within 20 years of developing diabetes. DR the principal cause of preventable vision loss in working-age adults around the world. There are two major clinical stages of diabetic retinopathy: a less severe subtype known as non-proliferative diabetic retinopathy (NPDR), and a vision-threatening subtype known as proliferative diabetic retinopathy (PDR). Signs of mild, moderate, and severe NPDR include microaneurysms, swollen blood vessels, retinal hemorrhages, vascular occlusion, and the accumulation of hard exudates in the choroid layer.

PDR is characterized by the growth of abnormal, new, fragile blood vessels in the retina. These vessels can leak, causing sudden and severe vision loss. Furthermore, abnormal new blood vessels formed in PDR can press on retinal veins, blocking blood flow, causing a condition known as retinal vein occlusion (RVO). Diabetic macular edema (DME) is a potential complication of DR that involves the macula, which is the small, oval-shaped part of the retina that is responsible for high acuity vision. DME is a condition where fluid accumulates within the macular area, causing swelling and retinal thickening. This can lead to sudden vision loss, resulting from the deterioration of the blood-retinal barrier.

Currently, only severe forms of diabetic retinopathy such as PDR and severe NPDR are managed with pharmacotherapy. The standard of care for DME and RVO are anti-angiogenic agents which inhibit vascular endothelial growth factor (VEGF). The most frequently used anti-VEGF drugs are Roche/Genentech's humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regeneron's fusion protein Eylea (aflibercept). Angiotensin converting enzyme (ACE) inhibitors can be used to treat patients with comorbid hypertension and diabetic retinopathy, while corticosteroids Alimera's Iluvien (fluocinolone acetonide), Allergan's Ozurdex (dexamethasone), and MaQaid (triamcinolone acetonide) can be used to treat people with RVO.

There are nine pharmaceutical markets covered in this report and forecast model (US, France, Germany, Italy, Spain, UK, Japan, China, and Australia). GlobalData estimates that drug sales for DR in 2019 were approximately $3.6B across the nine major markets. Over the 10-year forecast period, the market is expected to grow to $8.6B at a CAGR of 9.1%. This growth will be driven by the launch of longer-acting anti-angiogenic products, topical, and oral drug candidates, which are expected to increase patient compliance, addressing some of the key clinical unmet needs for this indication.

Key Highlights

  • The DR market is expected to grow at a CAGR of 9.1% from 2019 to 2029, reaching a global value of $8.6B.
  • GlobalData projects that the marketed for DR, DME, and RVO will experience growth driven by the launch of long-acting anti-angiogenic products, topical, and oral drug candidates.
  • Drug developers are also focusing on producing non-steroidal ocular implants and oral DME products that increase patients' compliance. These products will reduce the need for patients to attend frequent hospital appointments in order to receive treatment.
  • Despite the clear signs of innovation in the DR pipeline, growth will be limited by the loss of market exclusivity for the major brands of anti-VEGFs: Lucentis, Eylea, and Avastin. The emergence of biosimilars will also negatively impact sales by taking critical patient share away from branded products over the forecast window.
  • DME is the most sight-threatening complication of DR and this indication is the focus of most drug developers in this therapy area.
  • The top selling drug for non-proliferative diabetic retinopathy in 2029 will be Boehringer Ingelheim's BI-1467335 because the oral therapy is expected to be well received by patients who will appreciate the convenience of being table to self-administer the drug. Furthermore, BI-1467335 is expected to launch in the US, 5EU, Japan, and Australia by the end of the forecast window.
  • The top selling drug for proliferative diabetic retinopathy in 2029 will be Novartis' brolucizumab because of its established efficacy profile and lower frequency of administration, compared to Roche's Lucentis (ranibizumab) and Bayer/Regeneron's Eylea (aflibercept).
  • As well as Novartis' brolucizumab, other drugs that are specifically in development for retinal vein occlusion are Graybug Vision's sunitinib malate CR, Addmedica's hydroxyurea, and Chengdu Kanghong's conbercept.
  • Brolucizumab is expected to be the top selling drug in this cohort with conbercept taking the second position with estimated sales of $295.2M in 2029. Both brolucizumab and conbercept are marketed for age-related macular degeneration, have well understood safety and efficacy profiles, and are injected less frequently than Lucentis, Eylea, and Avastin.
  • Products focusing on inhibiting neovascularization will generate $6.8B in sales in 2029, followed by anti-neoplastic agents and erythropoietin modulators generating $431.6M and $421.7M in the final year of the forecast window, respectively.
  • Some unmet needs such as the need for a more manageable frequency of administration for intravitreal agents will be better addressed in markets such as the US and 5EU, where drugs such as Adverum
  • Biotechnologies' gene therapy ADVM-022 and Novartis' LKA-651 will launch.
  • The presence of first-in-class products in the pipeline is evidence of breakthroughs in research allowing more diverse therapeutic targets to be identified and explored in R&D strategies.

Key Questions Answered:

  • What were the key DR treatments in 2019?
  • When will the late stage pipeline products launch in each of the 9MM?
  • What are the major clinical and environmental unmet needs in the DR market?
  • What are the key opportunities for pharmaceutical companies developing drug candidates for DR, RVO, and DME?

Scope

  • Overview of DR, RVO, and DME including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized DR, RVO, and DME therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic retinopathy and retinal vein occlusion, and diabetic retinopathy and diabetic macular edema) forecast from 2019 to 2029.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DR, RVO, and DME markets.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DR, RVO, and DME therapy. The most promising candidates in Phase II and Phase III stages of development are profiled.
  • Analysis of the current and future market competition in the global DR, RVO, and DME therapeutics market. Insightful review of the key market drivers, opportunities, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global DR therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DR therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

2. Diabetic Retinopathy: Executive Summary

  • 2.1. Consistent Growth Will See the DR Market More than Double in Size from 2019-2029
  • 2.2. Novel Mechanisms of Action and Non-Invasive Routes of Administration Are Being Investigated in Clinical Trials
  • 2.3. Lack of Specific Therapies for Early-Stage DR is a Significant Unmet Need
  • 2.4. Reducing the Burden of Frequent Anti-VEGF Injections Is a Key Priority for Drug Developers
  • 2.5. Sales of Neovascularization Inhibitors Will Exceed $6B in 2029
  • 2.6. What Do Physicians Think?

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports
  • 3.3. Upcoming Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
  • 4.2. Classification or Staging Systems

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global and Historical Trends
  • 5.4. Forecast Methodology
  • 5.5. Epidemiological Forecast for Diabetic Retinopathy (2019-2029)
  • 5.6. Discussion

6. Disease Management

  • 6.1. Diagnosis Overview
  • 6.2. Treatment Overview
  • 6.3. Pharmacotherapeutic Interventions for DR, RVO, and DME
  • 6.4. Non-Pharmacotherapeutic Treatment Options for Diabetic Retinopathy
  • 6.5. US
  • 6.6. 5EU
  • 6.7. Asia-Pacific

7. Competitive Assessment

8. Unmet Needs and Opportunity Assessment

9. Pipeline Assessment

10. Current and Future Players

11. Market Outlook

12. Appendix

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.